# A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

> **NCT03666143** · PHASE1 · COMPLETED · sponsor: **BeiGene** · enrollment: 216 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT03666143
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-01-05
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666143, "A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03666143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*